Current and historical daily PE Ratio for InflaRx NV (
) from 2018 to Apr 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. InflaRx NV stock (MEX:IFRX) PE ratio as of Apr 24 2024 is 0.
More Details
InflaRx NV (MEX:IFRX) PE Ratio (TTM) Chart
InflaRx NV (MEX:IFRX) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1250
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| InflaRx NV PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-19 | At Loss |
| 2024-04-22 | At Loss | 2024-02-16 | At Loss |
| 2024-04-19 | At Loss | 2024-02-15 | At Loss |
| 2024-04-18 | At Loss | 2024-02-14 | At Loss |
| 2024-04-17 | At Loss | 2024-02-13 | At Loss |
| 2024-04-16 | At Loss | 2024-02-12 | At Loss |
| 2024-04-15 | At Loss | 2024-02-09 | At Loss |
| 2024-04-12 | At Loss | 2024-02-08 | At Loss |
| 2024-04-11 | At Loss | 2024-02-07 | At Loss |
| 2024-04-10 | At Loss | 2024-02-06 | At Loss |
| 2024-04-09 | At Loss | 2024-02-05 | At Loss |
| 2024-04-08 | At Loss | 2024-02-02 | At Loss |
| 2024-04-05 | At Loss | 2024-02-01 | At Loss |
| 2024-04-04 | At Loss | 2024-01-31 | At Loss |
| 2024-04-03 | At Loss | 2024-01-30 | At Loss |
| 2024-04-02 | At Loss | 2024-01-29 | At Loss |
| 2024-04-01 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2024-01-01 | At Loss |
| 2024-03-01 | At Loss | 2023-12-29 | At Loss |
| 2024-02-29 | At Loss | 2023-12-28 | At Loss |
| 2024-02-28 | At Loss | 2023-12-27 | At Loss |
| 2024-02-27 | At Loss | 2023-12-26 | At Loss |
| 2024-02-26 | At Loss | 2023-12-25 | At Loss |
| 2024-02-23 | At Loss | 2023-12-22 | At Loss |
| 2024-02-22 | At Loss | 2023-12-21 | At Loss |
| 2024-02-21 | At Loss | 2023-12-20 | At Loss |
InflaRx NV (MEX:IFRX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
InflaRx NV
ISIN : NL0012661870
Compare
Compare
Traded in other countries / regions
IFRX.USAIF0.GermanyIFRX.Mexico IPO Date
2018-07-05Description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers